Polycythemia vera (erythremia, Vaquez's disease, polycythemia rubra) - PV is a chronic neoplastic myeloproliferative disease with stem cell damage, proliferation of three hematopoietic lineages, increased production of red blood cells and, to a lesser extent, leukocytes and platelets. At a certain stage of the disease, myeloid metaplasia of the spleen occurs.

The incidence of polycythemia vera is approximately 1 random per 100 thousand population per year and in last years has an undoubted tendency to increase. Men get sick slightly more often than women (1.2:1). Average age sick people are 60 years old, patients under 40 years old make up only 5%.

Etiopathogenesis. Polycythemia vera is a clonal neoplastic disease, which is based on the transformation of a hematopoietic stem cell. Since malignant transformation occurs at the level of a pluripotent stem cell, all three lineages of hematopoiesis are involved in the process. In patients suffering from PV, there is an increased content of CFU-GEMM (colony-forming units - granulocytic, erythroid, macrophage and megakaryocyte) - progenitor cells close to a pluripotent stem cell. In cell culture, active proliferation of these cells occurs in the absence of erythropoietin. Low serum erythropoietin levels are a specific sign of PV. In the bone marrow, hyperplasia of predominantly erythroid cells, as well as granulocytic and megakaryocytic lineages, is observed. A characteristic feature is the presence of clusters of polymorphic megakaryocytes (from small to giant). Myelofibrosis is rarely observed at the time of diagnosis, but manifests itself clearly with a long course of the disease. Gradually, the number of reticulin and collagen fibers increases, myelofibrosis develops and myelopoiesis is reduced. The mass of circulating erythrocytes (MCE) increases, the hematocrit increases, the blood viscosity increases (there is a significant increase in the hemoglobin content in the blood (from 180 g/l and above), red blood cells (from 6.6 x 10 12 /l) and the hematocrit index (from 55 % and higher). These factors, along with thrombocytosis, lead to impaired microcirculation and thromboembolic complications. In parallel, myeloid metaplasia of the spleen is associated. In IP there is no specific cytogenetic marker, however, in a significant number of patients with IP in the stage of development of myelofibrosis, chromosomal anomalies.

Clinical picture changes with the course of the disease and is determined mainly by the stage of the disease. In the domestic literature, it is customary to distinguish four stages of IP, which reflect the pathological processes occurring in the bone marrow and spleen of patients

Stages:

I - initial, low-symptomatic (5 years or more):

the spleen is not palpable

moderate erythrocytosis

moderate plethora

in the bone marrow panmyelosis

Vascular and thrombotic complications are possible, but not common

External manifestations of the disease are plethora, acrocyanosis, erythromelalgia (burning pain, paresthesia in the fingertips) and itchy skin after washing. An increase in MCE and, consequently, in circulating blood volume leads to arterial hypertension. If the patient has previously suffered from hypertension, then the blood pressure level increases, and antihypertensive therapy becomes ineffective. The manifestations of coronary heart disease and cerebral atherosclerosis are aggravated. Since MCE increases gradually, plethora, an increase in the number of red blood cells and hemoglobin, signs of microcirculation disorder in a number of patients appear 2-4 years before the diagnosis is made.

II – erythremic, expanded (10-15 years):

A. Without myeloid metaplasia of the spleen

general condition is disturbed

pronounced plethora (Hb 200 g/l or more)

thrombotic complications (stroke, myocardial infarction, necrosis of the fingertips)

panmyelosis

erythromelalgia (pain in the limbs and bones)

In the picture of peripheral blood, in addition to erythrocytosis, neutrophilia is often present with a shift of the leukocyte formula to the left to single myelocytes, as well as basophilia and thrombocytosis. In the bone marrow, total three-line hyperplasia with pronounced megakaryocytosis is detected, and reticulin myelofibrosis is possible. But at this stage of the disease there is still no myeloid metaplasia of the spleen (MMS), and the observed splenomegaly is due to increased sequestration of erythrocytes and platelets. Vascular complications are more frequent and severe than in the first stage of the disease. In the pathogenesis of thrombosis important role plays an increase in MCE, leading to an increase in blood viscosity and a slowdown in blood flow, thrombocytosis, as well as dysfunction of the endothelium. Ischemia associated with impaired arterial blood flow is observed in 24-43% of patients. Thrombosis of cerebral vessels, coronary and blood supply organs predominates abdominal cavity arteries. Venous thrombosis is detected in 25-30% of patients and is the cause of death in approximately a third of patients suffering from PV. Thrombosis of the veins of the portal system and mesenteric veins is not uncommon. In a number of patients, it is thrombotic complications that become a manifestation of IP. Polycythemia vera may be accompanied by hemorrhagic syndrome: frequent nosebleeds and bleeding after tooth extraction. Hypocoagulation is based on a slowdown in the conversion of fibrinogen to fibrin, which occurs in proportion to the increase in hematocrit, and a violation of blood clot retraction. Erosion and ulcers of the stomach and duodenum considered as visceral complications of IP.

B. With myeloid metaplasia of the spleen (MMS).

hepatosplenomegaly

plethora is moderately expressed

panmyelosis

increased bleeding

thrombotic complications

Splenomegaly increases, the number of leukocytes increases, the shift of the leukocyte formula to the left becomes more pronounced. In the bone marrow - panmyelosis; Reticulin and focal collagen myelofibrosis gradually develops. The number of red blood cells and platelets decreases somewhat due to their increased destruction in the spleen, as well as the gradual replacement of hematopoietic tissue with fibrous tissue. At this stage, stabilization of the patient’s condition may be observed, the level of hemoglobin, red blood cells and platelets approaches normal without therapeutic measures.

III - anemic:

anemic sm (even pancytopenia)

severe myelofibrosis

liver, spleen enlarged

In the bone marrow, collagen myelofibrosis increases and myelopoiesis decreases. The hemogram shows anemia, thrombocytopenia, and pancytopenia. The clinical picture of the disease may include anemic and hemorrhagic syndromes, splenomegaly and cachexia increase. The outcome of the disease may be transformation into acute leukemia and myelodysplastic syndrome (MDS).

Diagnostics. Currently, the criteria developed by the American Polycythemia Vera Study Group (PVSG) are used to establish the diagnosis of polycythemia vera. You-

1) an increase in the mass of circulating red blood cells (more than 36 ml/kg for men and more than 32 ml/kg for women);

2) normal saturation of arterial blood with oxygen (pO2 more than 92%);

3) splenomegaly.

1) thrombocytosis (platelet count more than 400 x 10 9 /l);

2) leukocytosis (the number of leukocytes is more than 12 x 10 9 /lb without signs of infection);

3) activity alkaline phosphatase(neutrophils above 100 units in the absence of fever or infection);

4) high content of vitamin B12 (more than 900 pg/ml).

The diagnosis of IP is considered reliable if the patient has all three signs of category A, or if the first and second signs of category A and any two signs of category B are present.

Currently, the most important diagnostic sign is the characteristic histological picture bone marrow; hyperplasia of cells of erythroid, granulocytic and megakaryocyte lineages with a predominance of erythroid, accumulations of polymorphic megakaryocytes (from small to giant). Myelofibrosis is rarely observed at the time of diagnosis, but becomes distinct with a long course of the disease.

At stage I, polycythemia vera, characterized by isolated erythrocytosis, must be differentiated from secondary erythrocytosis, which is a response to any pathological process in the body and can be either true or relative.

Relative erythrocytosis is a consequence of hemoconcentration, that is, MCE is normal, but the plasma volume is reduced, which is observed with dehydration of the body (for example, taking diuretics, polyuria in patients with diabetes, vomiting and diarrhea), loss of a large amount of plasma due to burns.

True secondary erythrocytosis (MCE is increased, hematocrit is increased) is caused by increased production of erythropoietin. The latter is compensatory in nature and is caused by tissue hypoxia in people living at significant altitudes above sea level, in patients with pathologies of the cardiovascular and respiratory systems, and in smokers. This category also includes patients with hereditary hemoglobinopathies, characterized by an increased affinity of hemoglobin for oxygen, of which a smaller amount is released in the body tissues. Inadequate production of erythropoietin is observed in kidney diseases (hydronephrosis, vascular pathology, cysts, tumors, congenital anomalies), hepatocellular cancer, large uterine fibroids. An essential differential diagnostic feature is the level of serum erythropoietin.

Treatment. In the initial stages of the disease, it is recommended to use bloodletting, which significantly alleviates the manifestations of plethoric syndrome. The method of choice for reducing hematocrit (and hemoglobin to normal values) is bloodletting (exfusion), which is recommended if the hematocrit exceeds 0.54. The goal of treatment is a hematocrit of less than 0.42 for women and 0.45 for men. In modern conditions, bloodletting can be replaced by erythrocytepheresis. In addition, to facilitate bloodletting and prevent thrombotic complications, patients are given courses of disaggregant therapy (aspirin, rheopolyglucin, etc.). Choosing a treatment method at advanced stage II of IP is perhaps the most difficult task. In addition to erythrocytosis, patients have leukocytosis and thrombocytosis, and the latter can reach very high numbers. Some patients have already suffered some kind of thrombotic complications, and exfusions increase the risk of thrombosis.

When individualizing therapy, the age of the patients should be taken into account. This is the treatment of patients under 50 years of age, without a history of thrombotic complications and severe hyperthrombocytosis (< 1000,0 х 10 9 /л) может быть ограничено только кровопусканиями в сочетании с терапией аспирином (или без него) в дозе 100-375 мг в день.

For patients over 70 years of age, with a history of thrombotic complications and severe hyperthrombocytosis, therapy with myelosuppressive drugs is indicated. Patients 50 to 70 years of age without thrombotic complications or severe hyperthrombocytosis can be treated with myelosuppressive agents or phlebotomy, although the latter treatment may increase the risk of thrombotic complications.

Currently, in addition to bloodletting and antiplatelet agents, hydroxyurea and alpha-interferon are mainly used for the treatment of PV, less often busulfan, and anagrelide is used abroad. Hydroxyurea may be the drug of choice in patients with PV with severe leukocytosis and thrombocytosis. But for the sick young the use of hydroxyurea is limited by its mutagenic and leukemic effects. In addition to hydroxyurea, interferon-alpha is widely used in the treatment of PV. Firstly, IF-a suppresses pathological proliferation quite well and does not have a leukemic effect. Secondly, like hydroxyurea, it significantly reduces the production of platelets and white blood cells. Special attention deserves the ability of IF-a to eliminate skin itching caused by taking water procedures.

Aspirin in daily dose 50-250 mg, as a rule, eliminates microcirculation disorders. Taking this drug or other antiplatelet agents with therapeutic or for preventive purposes Recommended for all IP patients.

Unfortunately, there is currently no effective treatment for the III anemic stage of IP. Therapy is limited to palliatives. Anemic and hemorrhagic syndrome is corrected by transfusions of blood components. The effectiveness of hematopoietic stem cell transplantation in patients with PV in the stage of myelofibrosis with splenomegaly and pancytopenia and transformation into acute leukemia or MDS has been reported. The three-year survival rate of patients after transplantation was 64%.

Forecast. Despite the long and in some cases favorable course, IP is serious illness and is fraught with fatal complications that shorten the life expectancy of patients. Most common cause The deaths of patients are thrombosis and embolism (30-40%). In 20-50% of patients in the stage of post-polycythaemic myelofibrosis (IP stage III), transformation occurs into acute leukemia, which has an unfavorable prognosis - a three-year survival rate of only 30%.

Polycythemia vera (erythremia, Vaquez disease or primary polycythemia) is a progressive leukemia. malignant disease, which is associated with hyperplasia of cellular elements of the bone marrow (myeloproliferation). The pathological process primarily affects the erythroblastic germ, so an excess number of red blood cells is detected in the blood. An increase in the number of neutrophilic leukocytes and platelets is also observed.

ICD-10	D45
ICD-9	238.4
ICD-O	M9950/3
MedlinePlus	000589
MeSH	D011087

An increased number of red blood cells increases blood viscosity, increases its mass, causes a slowdown in blood flow in the vessels and the formation of blood clots. As a result, patients develop impaired blood supply and hypoxia.

General information

Polycythemia vera was first described in 1892 by the French physician and cardiologist Vaquez. Vaquez suggested that the hepatosplenomegaly and erythrocytosis detected in his patient arose as a result of increased proliferation of hematopoietic cells, and identified erythremia as a separate nosological form.

In 1903, W. Osler used the term “Vaquez disease” to describe patients with splenomegaly (enlarged spleen) and severe erythrocytosis and gave detailed description diseases.

Turk (W. Turk) in 1902-1904 suggested that in this disease the disorder of hematopoiesis is hyperplastic in nature, and called the disease erythremia by analogy with leukemia.

The clonal neoplastic nature of myeloproliferation, which is observed in polycythemia, was proven in 1980 by P. J. Fialkov. He discovered one type of enzyme, glucose-6-phosphate dehydrogenase, in red blood cells, granulocytes and platelets. In addition, both types of this enzyme were detected in the lymphocytes of two patients heterozygous for this enzyme. Thanks to Fialkov's research, it became clear that the target of the neoplastic process is the precursor cell of myelopoiesis.

In 1980, a number of researchers managed to separate normal cells neoplastic clone. It has been experimentally proven that polycythemia produces a population of erythroid committed precursors that are pathologically highly sensitive to even small amounts of erythropoietin (a kidney hormone). According to scientists, this contributes to increased formation of red blood cells in polycythemia vera.

In 1981, L. D. Sidorova and co-authors conducted studies that made it possible to detect qualitative and quantitative changes in the platelet component of hemostasis, which play a major role in the development of hemorrhagic and thrombotic complications in polycythemia.

Polycythemia vera is detected mainly in older people, but can be observed in young people and children. In young people, the disease is more severe. The average age of patients varies from 50 to 70 years. The average age of those who become ill for the first time is gradually increasing (in 1912 it was 44 years, and in 1964 - 60 years). The number of patients under 40 years of age is about 5%, and erythremia in children and patients under 20 years of age is detected in 0.1% of all cases of the disease.

Erythremia is slightly less common in women than in men (1: 1.2-1.5).

It is the most common disease in the group of chronic myeloproliferative diseases. It is quite rare - according to various sources, from 5 to 29 cases per 100,000 population.

There is isolated data on the influence of racial factors (above the average among Jews and below the average among representatives of the Negroid race), but at the moment this assumption has not been confirmed.

Forms

Polycythemia vera is divided into:

• Primary (not a consequence of other diseases).
• Secondary. It can be triggered by chronic lung disease, hydronephrosis, the presence of tumors (uterine fibroids, etc.), the presence of abnormal hemoglobins and other factors associated with tissue hypoxia.

An absolute increase in erythrocyte mass is observed in all patients, but only in 2/3 the number of leukocytes and platelets also increases.

Reasons for development

The causes of polycythemia vera have not been definitively established. Currently, there is no single theory that would explain the occurrence of hemoblastoses (blood tumors), to which this disease belongs.

Based on epidemiological observations, a theory was put forward about the connection of erythremia with the transformation of stem cells, which occurs under the influence of gene mutations.

It has been established that most patients have a mutation in the enzyme Janus kinase-tyrosine kinase, synthesized in the liver, which is involved in the transcription of certain genes by phosphorylating many tyrosines in the cytoplasmic part of the receptors.

The most common mutation, discovered in 2005, is in exon 14 JAK2V617F (detected in 96% of all cases of the disease). In 2% of cases, the mutation affects exon 12 of the JAK2 gene.

Patients with polycythemia vera also have:

• In some cases, mutations in the thrombopoietin receptor gene MPL. These mutations are of secondary origin and are not strictly specific for this disease. Identified in older people (mainly women) with low level hemoglobin and platelets.
• Loss of function of the LNK gene protein SH2B3, which reduces the activity of the JAK2 gene.

Elderly patients with a high JAK2V617F allelic load are characterized by increased level hemoglobin, leukocytosis and thrombocytopenia.

With a mutation of the JAK2 gene in exon 12, erythremia is accompanied by a subnormal serum level of the hormone erythropoietin. Patients with this mutation are younger.
In polycythemia vera, mutations of TET2, IDH, ASXL1, DNMT3A, etc. are also often detected, but their pathogenetic significance has not yet been studied.

Differences in survival of patients with different types no mutations were detected.

As a result of molecular genetic disorders, the JAK-STAT signaling pathway is activated, which is manifested by proliferation (cell production) of the myeloid lineage. At the same time, proliferation and an increase in the number of red blood cells in the peripheral blood increase (an increase in the number of leukocytes and platelets is also possible).

The identified mutations are inherited in an autosomal recessive manner.

There is also a hypothesis according to which the cause of erythremia may be viruses (15 types of such viruses have been identified), which, in the presence of predisposing factors and weakened immunity, penetrate into immature bone marrow cells or lymph nodes. Cells affected by the virus begin to actively divide instead of maturing, thus starting the pathological process.

Factors that provoke the disease include:

• X-ray irradiation, ionizing radiation;
• paints, varnishes and others toxic substances, penetrating the human body;
• long-term use in medicinal purposes some medications (gold salts for rheumatoid arthritis and etc.);
• viral and intestinal infection, tuberculosis;
• surgical interventions;
• stressful situations.

Secondary erythremia develops under the influence of favorable factors when:

• high innate affinity of hemoglobin for oxygen;
• low levels of 2,3-diphosphoglycerate;
• autonomous production of erythropoietin;
• arterial hypoxemia of a physiological and pathological nature (“blue” heart defects, smoking, adaptation to high altitude conditions and chronic lung diseases);
• kidney diseases (cystic lesions, hydronephrosis, stenosis renal arteries and diffuse diseases of the renal parenchyma);
• the presence of tumors (possibly influenced by bronchial carcinoma, cerebellar hemangioblastoma, uterine fibroids);
• endocrine diseases associated with adrenal tumors;
• liver diseases (cirrhosis, hepatitis, hepatoma, Budd-Chiari syndrome);
• tuberculosis.

Pathogenesis

The pathogenesis of polycythemia vera is associated with a disruption of the process of hematopoiesis (hematopoiesis) at the level of the progenitor cell. Hematopoiesis acquires the unlimited proliferation of progenitor cells characteristic of a tumor, the descendants of which form a specialized phenotype in all hematopoietic lineages.

Polycythemia vera is characterized by the formation of erythroid colonies in the absence of exogenous erythropoietin (the appearance of endogenous erythropoietin-independent colonies is a sign that distinguishes erythremia from secondary erythrocytosis).

The formation of erythroid colonies indicates a disruption in the implementation of regulatory signals that the myeloid cell receives from the external environment.

The basis of the pathogenesis of polycythemia vera is defects in genes encoding proteins that are responsible for maintaining myelopoiesis within the normal range.

A decrease in oxygen concentration in the blood causes a reaction in the interstitial cells of the kidneys that synthesize erythropoietin. The process occurring in interstitial cells concerns the work of many genes. The main regulation of this process is carried out by factor-1 (HIF-1), which is a heterodimeric protein consisting of two subunits (HIF-1alpha and HIF-1beta).

If the oxygen concentration in the blood is within normal limits, proline residues (the heterocyclic amino acid of the freely existing HIF-1 molecule) are hydroxylated under the influence of the regulatory enzyme PHD2 (molecular oxygen sensor). Thanks to hydroxylation, the HIF-1 subunit acquires the ability to bind to the VHL protein, which provides tumor prevention.

The VHL protein forms a complex with a number of E3 ubiquitin ligase proteins, which, after forming covalent bonds with other proteins, are sent to the proteasome and destroyed there.

During hypoxia, hydroxylation of the HIF-1 molecule does not occur; the subunits of this protein combine and form the heterodimeric HIF-1 protein, which travels from the cytoplasm to the nucleus. Once in the nucleus, the protein binds to special DNA sequences in the promoter regions of genes (the conversion of genes into protein or RNA is induced by hypoxia). As a result of these transformations, erythropoietin is released into the bloodstream by the interstitial cells of the kidneys.

By myelopoiesis precursor cells, the genetic program embedded in them is carried out as a result of the stimulating effect of cytokines (these small peptide control (signal) molecules bind to the corresponding receptors on the surface of the precursor cells).

When erythropoietin binds to the erythropoietin receptor EPO-R, dimerization of this receptor occurs, which activates Jak2, a kinase associated with the intracellular domains of EPO-R.

Jak2 kinase is responsible for signal transmission from erythropoietin, thrombopoietin and G-CSF (granulocyte colony-stimulating factor).

Due to the activation of Jak2-kinase, phospholation of a number of cytoplasmic target proteins occurs, which includes adapter proteins of the STAT family.

Erythremia was detected in 30% of patients with constitutive activation of the STAT3 gene.

Also, with erythremia, in some cases, a reduced level of expression of the thrombopoietin receptor MPL is detected, which is compensatory in nature. The decrease in MPL expression is secondary and is caused by genetic defect, responsible for the development of polycythemia vera.

A decrease in degradation and an increase in the level of the HIF-1 factor is caused by defects in the VHL gene (for example, representatives of the population of Chuvashia are characterized by a homozygous mutation 598C>T of this gene).

Polycythemia vera can be caused by abnormalities of chromosome 9, but the most common is a deletion of the long arm of chromosome 20.

In 2005, a point mutation in exon 14 of the Jak2 kinase gene (mutation JAK2V617F) was identified, which causes the replacement of the amino acid valine with phenylalanine in the pseudokinase domain JH2 of the JAK2 protein at position 617.

The JAK2V617F mutation in hematopoietic precursor cells in erythremia is presented in a homozygous form (the formation of the homozygous form is affected by mitotic recombination and duplication of the mutant allele).

When JAK2V617F and STAT5 are active, the level of reactive oxygen species increases, resulting in a transition of the cell cycle from G1 to S phase. Adapter protein STAT5 and active forms oxygen transmit a regulatory signal from JAK2V617F to the cyclin D2 and p27kip genes, which causes an accelerated transition of the cell cycle from the G1 to S phase. As a result, the proliferation of erythroid cells that carry a mutant form of the JAK2 gene increases.

In JAK2V617F-positive patients, this mutation is detected in myeloid cells, B- and T-lymphocytes and natural killer cells, which proves the proliferative advantage of defective cells compared to the norm.

Polycythemia vera in most cases is characterized by a fairly low ratio of mutant to normal allele in mature myeloid cells and early precursors. In the presence of clonal dominance, patients experience more severe clinical picture compared to patients without this defect.

Symptoms

Symptoms of polycythemia vera are associated with excess production of red blood cells, which increase blood viscosity. In most patients, the level of platelets, which cause vascular thrombosis, also increases.

The disease develops very slowly and initial stage is asymptomatic.
At later stages polycythemia vera manifests itself:

• plethoric syndrome, which is associated with increased blood supply to organs;
• myeloproliferative syndrome, which occurs with increased production of red blood cells, platelets and leukocytes.

Plethoric syndrome is accompanied by:

• Headaches.
• Feeling of heaviness in the head;
• Dizziness.
• Attacks of pressing, squeezing pain behind the sternum, which occurs during physical activity.
• Erythrocyanosis (redness of the skin to a cherry tint and a bluish tint of the tongue and lips).
• Redness of the eyes, which occurs as a result of dilation of blood vessels in them.
• A feeling of heaviness in the upper abdomen (left), which occurs as a result of an enlarged spleen.
• Skin itching, which occurs in 40% of patients ( specific sign diseases). It intensifies after water procedures and occurs as a result of irritation by the breakdown products of red blood cells of the nerve endings.
• An increase in blood pressure, which decreases well with bloodletting and decreases slightly with standard treatment.
• Erythromelalgia (sharp, burning pain in the fingertips that is relieved by taking blood thinners, or painful swelling and redness of the foot or lower third of the leg).

Myeloproliferative syndrome manifests itself:

• soreness in flat bones and joint pain;
• a feeling of heaviness in the right upper abdomen as a result of an enlarged liver;
• general weakness and increased fatigue;
• increase in body temperature.

Vein enlargement is also observed, especially noticeable in the neck area, Cooperman's sign (discoloration soft palate with normal coloration of the hard palate), ulcer of the duodenum and in some cases of the stomach, bleeding of the gums and esophagus, increased level uric acid. The development of heart failure and cardiosclerosis is possible.

Stages of the disease

Polycythemia vera is characterized by three stages of development:

• Initial, stage I, which lasts about 5 years (a longer period is possible). It is characterized by moderate manifestations of plethoric syndrome, the size of the spleen does not exceed the norm. A general blood test reveals a moderate increase in the number of red blood cells; increased formation of red blood cells is observed in the bone marrow (an increase in the number of all blood cells, with the exception of lymphocytes, is also possible). At this stage, complications practically do not arise.
• The second stage, which can be polycythemic (II A) and polycythemic with myeloid metaplasia of the spleen (II B). Form II A, lasting from 5 to 15 years, is accompanied by severe plethoric syndrome, enlargement of the liver and spleen, the presence of thrombosis, and bleeding. Tumor growth in the spleen is not detected. Possible iron deficiency due to frequent bleeding. A general blood test reveals an increase in the number of red blood cells, platelets and leukocytes. Scar changes are observed in the bone marrow. Form II B is characterized by progressive enlargement of the liver and spleen, the presence of tumor growth in the spleen, thrombosis, general exhaustion, and bleeding. A complete blood count can detect an increase in the number of all blood cells, with the exception of lymphocytes. Red blood cells take on different sizes and shapes, and immature blood cells appear. Scar changes in the bone marrow gradually increase.
• Anemic, stage III, which develops 15-20 years after the onset of the disease and is accompanied by a pronounced enlargement of the liver and spleen, extensive scar changes in the bone marrow, circulatory disorders, a decrease in the number of red blood cells, platelets and leukocytes. Transformation into acute or chronic leukemia is possible.

Diagnostics

Erythremia is diagnosed based on:

• Analysis of complaints, medical history and family history, during which the doctor clarifies when the symptoms of the disease appeared, what chronic diseases the patient has, whether there was contact with toxic substances, etc.
• Physical examination findings that pay attention to color skin. During palpation and with the help of percussion (tapping), the size of the liver and spleen is determined, pulse and blood pressure are also measured (may be elevated).
• A blood test that determines the number of red blood cells (the norm is 4.0-5.5x109 g/l), leukocytes (can be normal, increased or decreased), platelets (at the initial stage does not deviate from the norm, then an increase in the level is observed, and then a decrease ), hemoglobin level, color indicator (usually the norm is 0.86-1.05). ESR (erythrocyte sedimentation rate) is reduced in most cases.
• Urinalysis, which allows you to identify concomitant diseases or the presence of renal bleeding.
• A biochemical blood test that reveals the increased level of uric acid characteristic of many cases of the disease. To identify organ damage accompanying the disease, the level of cholesterol, glucose, etc. is also determined.
• Data from a bone marrow study, which is carried out using a puncture in the sternum and allows to identify advanced education red blood cells, platelets and white blood cells, as well as the formation of scar tissue in the bone marrow.
• Trepanobiopsy data, which most fully reflect the condition of the bone marrow. For research using special device trephine from the wing of the ilium, a column of bone marrow is taken along with bone and periosteum.

A coagulogram, iron metabolism studies are also performed, and the level of erythropoietin in the blood serum is determined.

Since chronic erythremia is accompanied by an enlargement of the liver and spleen, an ultrasound of the internal organs is performed. Ultrasound also detects the presence of hemorrhages.

To estimate the prevalence tumor process, SCT is performed (spiral CT scan) and MRI (magnetic resonance imaging).

To identify genetic abnormalities, a molecular genetic study of peripheral blood is performed.

Treatment

The goals of treatment for polycythemia vera are:

• prevention and therapy of thrombosis hemorrhagic complications;
• elimination of symptoms of the disease;
• reducing the risk of complications and development of acute leukemia.

Erythremia is treated with:

• Bloodletting, in which, to reduce blood viscosity, 200-400 ml of blood is removed in young people and 100 ml of blood in concomitant diseases heart or in older people. The course consists of 3 procedures, which are carried out at intervals of 2-3 days. Before the procedure, the patient takes medications that reduce blood clotting. Bloodletting is not performed in the presence of recent thrombosis.
• Hardware treatment methods (erythrocytapheresis), which remove excess red blood cells and platelets. The procedure is carried out at intervals of 5-7 days.
• Chemotherapy, which is used at stage II B, in the presence of an increase in the number of all blood cells, poor tolerance to bloodletting, or the presence of complications from internal organs or blood vessels. Chemotherapy is carried out according to a special regimen.
• Symptomatic therapy, including antihypertensive drugs for high blood pressure (ACE inhibitors are usually prescribed), antihistamines to reduce skin itching, antiplatelet agents that reduce blood clotting, hemostatic drugs for bleeding.

To prevent thrombosis, anticoagulants are used (usually prescribed acetylsalicylic acid 40-325 mg/day).

Nutrition for erythremia must meet the requirements of the treatment table according to Pevzner No. 6 (the amount of protein foods is reduced, red fruits and vegetables and foods containing dyes are excluded).

– chronic hemoblastosis, which is based on the unlimited proliferation of all myelopoiesis, predominantly erythrocyte. Clinically, polycythemia is manifested by cerebral symptoms (heaviness in the head, dizziness, tinnitus), thrombohemorrhagic syndrome (arterial and venous thrombosis, bleeding), microcirculatory disorders (chillness of the extremities, erythromelalgia, hyperemia of the skin and mucous membranes). Basic diagnostic information is obtained from the study of peripheral blood and bone marrow. To treat polycythemia, bloodletting, erythrocytapheresis, and chemotherapy are used.

General information

Causes of polycythemia

The development of polycythemia is preceded by mutational changes in the pluripotent hematopoietic stem cell, which gives rise to all three bone marrow cell lines. The most common mutation detected is the JAK2 tyrosine kinase gene with the replacement of valine by phenylalanine at position 617. Sometimes there is a familial incidence of erythremia, for example, among Jews, which may indicate a genetic correlation.

In polycythemia, there are 2 types of erythroid hematopoietic precursor cells in the bone marrow: some of them behave autonomously, their proliferation is not regulated by erythropoietin; others, as expected, are erythropoietin-dependent. It is believed that the autonomous population of cells is nothing more than a mutant clone - the main substrate of polycythemia.

In the pathogenesis of erythremia, the leading role belongs to enhanced erythropoiesis, which results in absolute erythrocytosis, impaired rheological and coagulation properties of blood, myeloid metaplasia of the spleen and liver. High blood viscosity causes a tendency to vascular thrombosis and hypoxic tissue damage, and hypervolemia causes increased blood supply to internal organs. At the end of polycythemia, depletion of hematopoiesis and myelofibrosis are noted.

Classification of polycythemia

In hematology, there are 2 forms of polycythemia - true and relative. Relative polycythemia develops when normal level red blood cells and decreased plasma volume. This condition is called stress or false polycythemia and is not discussed within the scope of this article.

Polycythemia vera (erythremia) can be primary or secondary in origin. The primary form is an independent myeloproliferative disease, which is based on damage to the myeloid lineage of hematopoiesis. Secondary polycythemia usually develops with increased erythropoietin activity; this state is a compensatory reaction to general hypoxia and can occur in chronic pulmonary pathology, “blue” heart defects, adrenal tumors, hemoglobinopathies, when climbing to altitude or smoking, etc.

Polycythemia vera goes through 3 stages in its development: initial, advanced and terminal.

Stage I(initial, asymptomatic) – lasts about 5 years; is asymptomatic or with minimally expressed clinical manifestations. Characterized by moderate hypervolemia, slight erythrocytosis; The size of the spleen is normal.

Stage II(erythremic, expanded) is divided into two substages:

• IA – without myeloid transformation of the spleen. Erythrocytosis, thrombocytosis, and sometimes pancytosis are noted; according to the myelogram - hyperplasia of all hematopoietic germs, pronounced megakaryocytosis. The duration of the advanced stage of erythremia is 10-20 years.
• IIB – with the presence of myeloid metaplasia of the spleen. Hypervolemia, hepato- and splenomegaly are pronounced; in peripheral blood - pancytosis.

Stage III(anemic, posterythremic, terminal). Characterized by anemia, thrombocytopenia, leukopenia, myeloid transformation of the liver and spleen, secondary myelofibrosis. Possible outcomes of polycythemia into other hemoblastoses.

Symptoms of polycythemia

Erythremia develops over a long period of time, gradually, and can be detected accidentally during a blood test. Early symptoms, such as heaviness in the head, tinnitus, dizziness, blurred vision, chilliness of the extremities, sleep disturbance, etc., are often “written off” to old age or concomitant diseases.

Most characteristic feature polycythemia is the development of plethoric syndrome caused by pancytosis and an increase in blood volume. Evidence of plethora is telangiectasia, cherry-red coloring of the skin (especially the face, neck, hands and other open areas) and mucous membranes (lips, tongue), hyperemia of the sclera. Typical diagnostic sign Cooperman's symptom is used - the color of the hard palate remains normal, and the soft palate acquires a stagnant cyanotic tint.

To others distinctive symptom polycythemia is skin itching, which intensifies after water procedures and sometimes becomes unbearable. Specific manifestations of polycythemia also include erythromelalgia - a painful burning sensation in the fingertips, which is accompanied by their hyperemia.

In the advanced stage of erythremia, painful migraines, bone pain, cardialgia, and arterial hypertension may occur. 80% of patients have moderate or severe splenomegaly; the liver enlarges somewhat less frequently. Many patients with polycythemia notice increased bleeding of the gums, bruising of the skin, prolonged bleeding after tooth extraction.

The consequence of ineffective erythropoiesis in polycythemia is an increase in the synthesis of uric acid and a violation purine metabolism. This finds clinical expression in the development of the so-called urate diathesis - gout, urolithiasis, renal colic.

The result of microthrombosis and disruption of the trophism of the skin and mucous membranes are trophic ulcers of the leg, gastric and duodenal ulcers. The most common complications in the polycythemia clinic are vascular thrombosis of the deep veins, mesenteric vessels, portal veins, cerebral and coronary arteries. Thrombotic complications (PE, ischemic stroke, myocardial infarction) are the leading causes of death in patients with polycythemia. At the same time, along with thrombus formation, patients with polycythemia are prone to hemorrhagic syndrome with the development of spontaneous bleeding of various locations (gingival, nasal, from the esophageal veins, gastrointestinal, etc.).

Diagnosis of polycythemia

Hematological changes characterizing polycythemia are decisive in the diagnosis. A blood test reveals erythrocytosis (up to 6.5-7.5x10 12 /l), increased hemoglobin (up to 180-240 g/l), leukocytosis (over 12x10 9 /l), thrombocytosis (over 400x10 9 /l). The morphology of erythrocytes, as a rule, is not changed; with increased bleeding, microcytosis may be detected. Reliable confirmation of erythremia is an increase in the mass of circulating red blood cells of more than 32-36 ml/kg.

To study the bone marrow in polycythemia, it is more informative to conduct a non-gastroenterologist or urologist.

Treatment and prognosis of polycythemia

In order to normalize the volume of the bcc and reduce the risk of thrombotic complications, the first measure is bloodletting. Blood exfusions are carried out in a volume of 200-500 ml 2-3 times a week, followed by replenishment of the removed blood volume with saline solution or rheopolyglucin. The consequence of frequent bloodletting may be the development of iron deficiency anemia. Bloodletting for polycythemia can be successfully replaced by erythrocytepheresis, which allows only the red blood cell mass to be removed from the bloodstream, returning the plasma.

In case of pronounced clinical and hematological changes, the development of vascular and visceral complications, they resort to myelosuppressive therapy with cytostatics (busulfan, mitobronitol, cyclophosphamide, etc.). Radioactive phosphorus therapy is sometimes given. To normalize the state of aggregation of the blood, heparin, acetylsalicylic acid, dipyridamole are prescribed under the control of a coagulogram; for hemorrhages, platelet transfusions are indicated; for urate diathesis - allopurinol.

The course of erythremia is progressive; the disease is not prone to spontaneous remissions and spontaneous cure. Patients are forced to be under the supervision of a hematologist for life and undergo courses of hemoexfusion therapy. With polycythemia there is a high risk of thromboembolic and hemorrhagic complications. The incidence of transformation of polycythemia into leukemia is 1% in patients who have not undergone chemotherapy treatment, and 11-15% in those receiving cytotoxic therapy.

Polycythemia – chronic illness, in which there is an increase in the number of red cells or red blood cells in the blood. Middle-aged and older people are susceptible to the disease - men are affected several times more often than women. More than half of people experience an increase in the number of platelets and white blood cells.

The occurrence of a disease can be due to several reasons, which separate its types. Primary or polycythemia vera is caused mainly by genetic abnormalities or bone marrow tumors, while secondary polycythemia is caused by external or internal influences. Without proper treatment it leads to severe complications, the prognosis of which is not always reassuring. Thus, the primary form, if therapy is not started in a timely manner, can lead to fatal outcome over several years of progression, and the outcome of the secondary depends on the cause of its appearance.

The main symptoms of the disease are seizures severe dizziness and tinnitus, a person feels as if he is losing consciousness. Treatment uses bloodletting and chemotherapy.

A distinctive feature of this disorder is that it cannot disappear spontaneously and it is also impossible to completely recover from it. The person will need to undergo regular blood tests and be under the supervision of doctors for the rest of his life.

Etiology

The causes of the disease depend on its form and can be caused by various factors. Polycythemia vera occurs when:

• hereditary predisposition to production disorders;
• genetic failures;
• malignant neoplasms in the bone marrow;
• the effects of hypoxia (oxygen deficiency) on red cells in the blood.

Secondary polycythemia is caused by:

• chronic heart failure;
• insufficient supply of blood and oxygen to the kidneys;
• climatic conditions. People living in high mountain areas are most susceptible;
• oncological tumors of internal organs;
• various infectious diseases, causing intoxication of the body;
• harmful working conditions, for example, in a mine or at height;
• living in polluted cities or near factories;
• long-term nicotine abuse;
• nation. According to statistics, polycythemia occurs in people Jewish origin, this is due to genetics.

The disease itself is rare, but polycythemia in newborns is even rarer. The main method of transmission of the disease is through the mother's placenta. The baby's place does not provide sufficient oxygen to the fetus (poor blood circulation).

Varieties

As mentioned above, the disease is divided into several types, which directly depend on the causes of occurrence:

• primary or true polycythemia - caused by blood pathologies;
• secondary polycythemia, which can be called relative - caused by external and internal pathogens.

Polycythemia vera, in turn, can occur in several stages:

• initial, which is characterized by a slight manifestation of symptoms or their complete absence. May last for five years;
• expanded. It is divided into two forms - without a malignant effect on the spleen and with its presence. The stage lasts one or two decades;
• severe – observed, education cancerous tumors on internal organs, including the liver and spleen, malignant blood lesions.

Relative polycythemia occurs:

• stressful - based on the name, it becomes clear that it occurs when the body is affected by prolonged overexertion, unfavorable working conditions and an unhealthy lifestyle;
• false - in which the level of red blood cells and in the blood is within normal limits.

The prognosis of polycythemia vera is considered unfavorable; life expectancy with this disease does not exceed two years, but the chances of a long life increase when used in the treatment of bloodletting. In this case, a person will be able to live fifteen or more years. The prognosis of secondary polycythemia completely depends on the course of the disease, which triggered the process of increasing the number of red cells in the blood.

Symptoms

On initial stage Polycythemia occurs with virtually no symptoms. It is usually discovered during a random examination or during preventive blood tests. The first symptoms may be mistaken for a common cold or indicate normal condition in older people. These include:

• decreased visual acuity;
• severe dizziness and headaches;
• noise in ears;
• sleep disturbance;
• cold tips of the fingers of the extremities.

In the advanced stage, the following symptoms may be observed:

• muscle and bone pain;
• an increase in the size of the spleen, the volume of the liver changes slightly less frequently;
• bleeding gums;
• continuous bleeding for quite a long time after tooth extraction;
• the appearance of bruises on the skin, the nature of which a person cannot explain.

Besides, specific symptoms of this disease are:

• severe itching of the skin, which is characterized by an increase in intensity after taking a bath or shower;
• painful burning sensations in the tips of the fingers and toes;
• manifestation of veins that were not previously noticeable;
• the skin of the neck, hands and face takes on a bright red color;
• lips and tongue acquire a bluish tint;
• the whites of the eyes become bloodshot;
• general weakness of the patient's body.

In newborns, especially twins, symptoms of polycythemia begin to appear within a week after birth. These include:

• redness of the baby's skin. The child begins to cry and scream when touched;
• significant reduction in body weight;
• a large number of red blood cells, leukocytes and platelets are found in the blood;
• The volumes of the liver and spleen increase.

These signs can lead to the death of the baby.

Complications

Consequence of ineffective or untimely treatment I can be:

• allocation to large quantities uric acid. Urine becomes concentrated and acquires an unpleasant odor;
• education ;
• chronic;
• occurrence and;
• circulatory disorders, which leads to trophic ulcers on the skin;
• hemorrhages in various locations, for example, nose, gums, gastrointestinal tract, etc.

And they are considered the most common causes of death for patients with this disease.

Diagnostics

Polycythemia is very often discovered accidentally during a blood test for completely different reasons. When diagnosing, the doctor must:

• carefully review the medical history of the patient and his immediate family;
• conduct a thorough examination of the patient;
• find out the cause of the disease.

The patient, in turn, must undergo the following examinations:

Treatment primary disease a rather labor-intensive process that includes influencing tumors and preventing their activity. In drug therapy, the age of the patient plays an important role, because those substances that will help people under fifty years of age will be strictly prohibited for treating patients over seventy.

With a high content of red blood cells in the blood in the best possible way The treatment is bloodletting - during one procedure, the blood volume is reduced by approximately 500 milliliters. More modern method The treatment for polycythemia is cytopheresis. The procedure involves filtering the blood. To do this, catheters are inserted into the veins of both arms of the patient, blood enters the machine through one, and after filtration, the purified blood is returned to the other vein. This procedure must be done every other day.

For secondary polycythemia, treatment will depend on the underlying disease and the severity of its symptoms.

Prevention

Most causes of polycythemia cannot be prevented, but despite this, there are several preventive measures:

• completely stop smoking;
• change place of work or residence;
• promptly treat diseases that can cause this disorder;
• undergo regular preventive examinations at the clinic and take blood tests.

Polycythemia (erythremia, Vaquez's disease): causes, signs, course, therapy, prognosis

Polycythemia is a disease that can be assumed just by looking at the patient's face. And if you also carry out the necessary blood test, then there will be no doubt at all. In reference books it can also be found under other names: erythremia and Vaquez disease.

Redness of the face is quite common and there is always an explanation for this. In addition, it is short-term and does not last long. Various reasons can cause sudden redness of the face: fever, increased blood pressure, recent sunburn, awkward situation, and emotionally labile people generally tend to blush often, even if those around them do not see any prerequisites for this.

Polycythemia is different. Here The redness is persistent, not transient, evenly distributed throughout the face. The color of excessively “healthy” plethora is rich, bright cherry.

What kind of disease is polycythemia?

Polycythemia vera (erythremia, Vaquez disease) belongs to the group of hemoblastoses (erythrocytosis) or chronic ones with a benign course. The disease is characterized by the proliferation of all three sprouts of hematopoiesis with a significant advantage of the erythrocyte and megakaryocyte, due to which there is an increase not only in the number of red blood cells, but also in other blood cells that originate from these sprouts, where the source of the tumor process is the affected myelopoiesis precursor cells. They are the ones who begin uncontrolled proliferation and differentiation into mature forms of red blood cells.

The ones that suffer the most under such conditions are immature red blood cells, which are hypersensitive to erythropoietin even in small doses. For polycythemia At the same time, an increase in leukocytes of the granulocytic series is observed(primarily band and neutrophils)and platelets. Cells of the lymphoid series, which include lymphocytes, are not affected by the pathological process, since they come from a different germ and have a different path of reproduction and maturation.

Cancer or not cancer?

Erythremia is not to say that it occurs all the time, but in a town of 25 thousand people there are a couple of people, while for some reason men of about 60 years of age or so “like” this disease more, although anyone can encounter such a pathology age. True, for newborns and children younger age polycythemia vera is absolutely uncharacteristic, therefore if erythremia is detected in a child, then most likely she will carry secondary character and be a symptom and consequence of another disease (toxic dyspepsia, stress erythrocytosis).

For many people, the disease classified as leukemia (and it does not matter: acute or chronic) is primarily associated with blood cancer. Here it is interesting to figure out: is it cancer or not? In this case, it would be more expedient, clearer and more correct to talk about the malignancy or benignity of polycythemia vera in order to determine the boundary between “good” and “evil”. But, since the word “cancer” refers to tumors from epithelial tissues, then in this case this term is inappropriate, because this tumor comes from hematopoietic tissue.

Vaquez disease refers to malignant tumors , but is characterized by high cell differentiation. The course of the disease is long and chronic, for the time being qualified as benign. However, such a course can last only up to a certain point, and then with the right and timely treatment, but after some period of time, when significant changes occur in erythropoiesis, the disease turns into acute form and acquires more “evil” traits and manifestations. This is what it is like – true polycythemia, the prognosis of which will depend entirely on how quickly it progresses.

Why do sprouts grow incorrectly?

Any patient suffering from erythremia sooner or later asks the question: “Why did this “disease” happen to me?” Searching for the reason of many pathological conditions, as a rule, is useful and gives certain results, increases the effectiveness of treatment and promotes recovery. But not in the case of polycythemia.

The causes of the disease can only be assumed, but not stated unambiguously. There can only be one clue for a doctor to find out the origin of the disease - genetic abnormalities. However, the pathological gene has not yet been found, so the exact localization of the defect has not yet been determined. There are, however, suggestions that Vaquez disease may be associated with trisomy 8 and 9 pairs (47 chromosomes) or another disorder of the chromosomal apparatus, for example, loss of a section (deletion) of the long arm C5, C20, but these are still guesses, although based on conclusions of scientific research.

Complaints and clinical picture

If there is nothing to say about the causes of polycythemia, then a lot can be said about the clinical manifestations. They are bright and varied, since already from the 2nd stage of development of the disease, literally all organs are involved in the process. The patient’s subjective sensations are of a general nature:

• Weakness and constant feeling of fatigue;
• Significant decrease in performance;
• Increased sweating;
• Headaches and dizziness;
• Noticeable memory loss;
• Visual and auditory disorders (decreased).

Complaints specific to this disease and characterized by it:

• Acute burning pain in the fingers and toes (vessels become clogged with platelets and red blood cells, which form small aggregates there);
• The pain, however, is not so burning, in the upper and lower extremities;
• Itching of the body (a consequence of thrombosis), the intensity of which noticeably increases after a shower and hot bath;
• Periodic appearance of a rash such as urticaria.

It's obvious that cause all these complaints - microcirculation disorder.

As the disease further develops, more and more new symptoms are formed:

1. skin and mucous membranes due to the expansion of capillaries;
2. Pain in the heart area, reminiscent of;
3. Painful sensations in the left hypochondrium caused by overload and enlargement of the spleen due to the accumulation and destruction of platelets and red blood cells (it is a kind of depot for these cells);
4. Enlarged liver and spleen;
5. Peptic ulcer of the stomach and duodenum;
6. Dysuria (difficulty urinating) and pain in the lumbar region due to the development of uric acid diathesis, caused by a shift in the buffer systems of the blood;
7. Pain in bones and joints as a result hyperplasia(excessive growth) bone marrow;
8. Gout;
9. Manifestations of a hemorrhagic nature: bleeding (nose, gum, intestinal) and skin hemorrhages;
10. Injections of conjunctival vessels, which is why the eyes of such patients are called “rabbit eyes”;
11. Tendency to and arteries;
12. shins;
13. Possible thrombosis coronary vessels with development ;
14. Intermittent claudication, which may result in gangrene;
15. (almost 50% of patients), giving rise to a tendency to strokes and heart attacks;
16. Damage to the respiratory system due to immunity disorders, which cannot adequately respond to infectious agents that cause inflammatory processes. In this case, red blood cells begin to behave like suppressors and suppress the immunological response to viruses and tumors. In addition, they are found in abnormally high quantities in the blood, which further aggravates the condition of the immune system;
17. Kidneys suffer and urinary tract, so patients have a tendency to pyelonephritis, urolithiasis;
18. The central system does not remain aloof from events occurring in the body. nervous system, when it is involved in the pathological process, symptoms appear (with thrombosis), (less often), insomnia, memory impairment, and mnestic disorders.

From asymptomatic period to terminal stage

Due to the fact that for polycythemia in the first stages it is typical asymptomatic , the above manifestations do not occur in one day, but accumulate gradually and over a long period of time; in the development of the disease, it is customary to distinguish 3 stages.

Initial stage. The patient's condition is satisfactory, the symptoms are moderate, the duration of the stage is about 5 years.

Stage of advanced clinical manifestations. It takes place in two stages:

II A – occurs without myeloid metaplasia of the spleen, subjective and objective symptoms of erythremia are present, the duration of the period is 10-15 years;

II B – myeloid metaplasia of the spleen appears. This stage is characterized by a clear picture of the disease, the symptoms are pronounced, the liver and spleen are significantly enlarged.

Terminal stage, having all the signs of a malignant process. The patient’s complaints are varied, “everything hurts, everything is wrong.” At this stage, cells lose the ability to differentiate, thereby creating a substrate for leukemia, which replaces chronic erythremia, or rather, it turns into acute leukemia.

The terminal stage is characterized by a particularly severe course (hemorrhagic syndrome, rupture of the spleen, infectious and inflammatory processes that cannot be treated due to profound immunodeficiency). Usually it soon ends in death.

Thus, the life expectancy for polycythemia is 15-20 years, which may not be bad, especially considering that the disease can occur after 60. This means that there is some prospect of living up to 80 years. However, the prognosis of the disease still depends most on its outcome, that is, on what form of leukemia erythremia transforms into at stage III (chronic myeloid leukemia, myelofibrosis, acute leukemia).

Diagnosis of Vaquez disease

The diagnosis of polycythemia vera is primarily based on findings laboratory research with the determination of the following indicators:

• , in which you can notice a significant increase in red blood cells (6.0-12.0 x 10 12 / l), (180-220 G / l), (ratio of plasma and red blood). The number of platelets can reach a level of 500-1000 x 10 9 / l, while they can significantly increase in size, and leukocytes - up to 9.0-15.0 x 10 9 / l (due to rods and neutrophils). with polycythemia vera it is always reduced and can reach zero.

Morphologically, red blood cells do not always change and often remain normal, but in some cases with erythremia one can observe anisocytosis(red blood cells different sizes). The severity and prognosis of the disease with polycythemia in a general blood test is indicated by platelets (the more of them, the more severe the course of the disease);

• TANK ( biochemical analysis blood) with determination of the level And . For erythremia, the accumulation of the latter is very characteristic, which indicates the development of gout (a consequence of Vaquez's disease);
• Radiological testing using radioactive chromium helps determine the increase in circulating red blood cells;
• Sternal puncture (bone marrow collection from the sternum) followed by cytological diagnosis. In the preparation – hyperplasia of all three lineages with a significant predominance of red and megakaryocytic;
• Trephine biopsy(histological examination of material taken from the ilium) - the most informative method, allowing you to most reliably identify main feature diseases – three-line hyperplasia.

In addition to hematological parameters, to establish a diagnosis of polycythemia vera, the patient is referred to ultrasonography(ultrasound) of the abdominal organs (enlarged liver and spleen).

So, the diagnosis has been made... What next?

And then the patient awaits treatment in the hematology department, where the tactics are determined clinical manifestations, hematological parameters and stage of the disease. Treatment measures for erythremia usually include:

1. Bloodletting, which allows you to reduce the number of red blood cells to 4.5-5.0 x 10 12 / l and Hb (hemoglobin) to 150 g / l. To do this, 500 ml of blood is taken at intervals of 1-2 days until the number of red blood cells and Hb drops. Hematologists sometimes replace the bloodletting procedure with erythrocytopheresis, when, after collection by centrifugation or separation, red blood is separated and the plasma is returned to the patient;
2. Cytostatic therapy (myelosan, imifos, hydroxyurea, hydroxyurea);
3. (aspirin, dipyridamole), which, however, require caution in use. Thus, acetylsalicylic acid can enhance the manifestation of hemorrhagic syndrome and cause internal bleeding if the patient has a stomach or duodenal ulcer;
4. Interferon-α2b, successfully used with cytostatics and increasing their effectiveness.

The treatment regimen for erythremia is prescribed by the doctor individually for each case, so our task is only to briefly introduce the reader to the drugs used to treat Vaquez disease.

Nutrition, diet and folk remedies

A significant role in the treatment of polycythemia is given to the work regime (reducing physical activity), rest and nutrition. In the initial stage of the disease, when the symptoms are not yet expressed or are weakly manifested, the patient is assigned to table No. 15 (general), albeit with some reservations. The patient is not recommended to consume foods that enhance hematopoiesis.(liver, for example) and suggest revising the diet, giving preference to dairy and plant products.

In the second stage of the disease, the patient is prescribed table No. 6, which corresponds to the diet for gout and limits or completely excludes fish and meat dishes, legumes and sorrel. After being discharged from the hospital, the patient must adhere to the recommendations given by the doctor during outpatient observation or treatment.

Question: “Is it possible to treat folk remedies? sounds with the same frequency for all diseases. Erythremia is no exception. However, as already noted, the course of the disease and the patient’s life expectancy depend entirely on timely treatment, the goal of which is to achieve a long and stable remission and delay the third stage for as long as possible.

During a period of calm pathological process the patient must still remember that the disease can return at any time, so he must discuss his life without an exacerbation with the attending physician with whom he is being observed, periodically take tests and undergo examinations.

Treatment of blood diseases with folk remedies should not be generalized, and if there are many recipes for increasing hemoglobin levels or for, this does not mean at all that they are suitable for the treatment of polycythemia, from which, in general, no medicinal herbs have been found yet. Vaquez's disease is a delicate matter, and in order to control the function of the bone marrow and thus influence the hematopoietic system, you need to have objective data that can be assessed by a person with certain knowledge, that is, the attending physician.

In conclusion, I would like to say a few words to the readers about relative erythremia, which cannot be confused with the true one, since relative erythrocytosis can occur against the background of many somatic diseases and end successfully when the disease is cured. In addition, erythrocytosis as a symptom may accompany prolonged vomiting, diarrhea, burn disease and hyperhidrosis. IN similar cases erythrocytosis is a temporary phenomenon and is associated primarily with dehydration of the body, when the amount of circulating plasma, which consists of 90% water, decreases.

Video: polycythemia in the program “Live Healthy!”